Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | TNF | P01375 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4445007 | 0.89 | MEN1 (0.72) | MEN1KMT2ATP53MAPTRAB9A | |
| SCHEMBL9949593 | 0.86 | TNF (0.70) | MEN1KMT2ATP53MAPTTNF | |
| SCHEMBL825515 | 0.85 | MEN1 (0.71) | MEN1KMT2ATP53MAPTPOLB | |
| SCHEMBL7746552 | 0.85 | PDE4A (0.71) | MEN1KMT2ATP53MAPTTNF | |
| SCHEMBL5515814 | 0.84 | MEN1 (0.66) | MEN1KMT2ATP53MAPTRAB9A | |
| SCHEMBL6694788 | 0.82 | TNF (0.77) | TNF | |
| SCHEMBL5512040 | 0.81 | MEN1 (0.61) | MEN1KMT2ATP53MAPTRAB9A | |
| SCHEMBL5941456 | 0.80 | PDE4A (0.69) | MEN1KMT2ATP53MAPTTNF | |
| SCHEMBL717039 | 0.80 | PDE4A (0.69) | MEN1KMT2ATP53MAPTTNF | |
| SCHEMBL29840774 | 0.80 | PDE4A (0.69) | MEN1KMT2ATP53MAPTTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080138295-A1 | Bechet's disease using cyclopropyl-N-carboxamide | CELGENE COPORATION | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138295-A1 | Bechet's disease using cyclopropyl-N-carboxamide | IL2, TNF, FGF2 | MEN1 1111/4885KMT2A 1325/4885TP53 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.